Genovese MC, et al. - In this study, the effects of baseline characteristics, including prior biologic DMARDs (bDMARDs) exposure, were comprehensively analyzed on the baricitinib efficacy and safety in patients with rheumatoid arthritis. Based on the results, baricitinib illustrated a consistent, beneficial therapeutic effect in bDMARD-refractory patients across subgroups, based on baseline characteristics and prior bDMARD use.